Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs

Dan L. Eisenberg, Carol B. Toris, Carl B. Camras

Research output: Contribution to journalArticlepeer-review

96 Scopus citations


Bimatoprost (Lumigan™ [Allergan, Inc, Irvine CA]) and travoprost (Travatan™ [Alcon, Ft Worth, TX]) are two new intraocular pressure (IOP)-lowering drugs for use in patients with glaucoma and ocular hypertension. This review evaluates recent studies comparing these new drugs with timolol and with latanoprost. In each study, the statistical analyses support the conclusion that these agents were more effective than timolol and as effective as latanoprost in terms of their ability to reduce IOP. The side effect profiles for bimatoprost, latanoprost, and travoprost were similar, but with statistically higher occurrences of hyperemia and eyelash growth for bimatoprost or travoprost versus latanoprost or timolol.

Original languageEnglish (US)
Pages (from-to)S105-S115
JournalSurvey of Ophthalmology
Issue number4 SUPPL. 1
StatePublished - Aug 2002


  • Bimatoprost
  • Glaucoma
  • Intraocular pressure
  • Latanoprost
  • Ocular hypertension
  • Timolol
  • Travoprost

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs'. Together they form a unique fingerprint.

Cite this